Education: PhD from the Royal Institute of Technology in Stockholm and an Executive MBA from Stockholm University.
Experience: Christina Herder (born 1961) has 30 years of experience in pharmaceutical development and business development in the life science industry. Her previous assignments include several leading roles in, among others, SOBI and Biovitrum. Christina has worked as CEO of Modus Therapeutics, EVP Business Development at Medivir and CEO of Idogen. She has also been the member of several boards and is current a board member in Beactica Therapeutics.
Independency: Christina Herder is independent in relation to the company, its senior executives and major shareholders.
Shares: 84 400 (incl. related parties).
Warrants (TO2): 21 700 (incl. related parties).
